Wayside Technology Group, Inc. (NASDAQ:WSTG) shares advanced 2.98% in last trading session and ended the day at $19.02. WSTG Gross Margin is 7.00% and its has a return on assets of 6.60%. Wayside Technology Group, Inc. (NASDAQ:WSTG) quarterly performance is 2.64%.
Wayside Technology Group, Inc. (NASDAQ:WSTG) reported third-quarter profit of $1.6 million.On a per-share basis, the Shrewsbury, New Jersey-based company said it had net income of 33 cents.
The computer software reseller posted revenue of $97.7 million in the period. Wayside Technology shares have climbed 4 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $17.90, an increase of 4 percent in the last 12 months.
Apple Inc. (NASDAQ:AAPL) caters to the Consumer Goods space. It has a net profit margin of 22.80% and weekly performance is 5.12%. On the last day of trading company shares ended up at $121.18. Apple Inc. (NASDAQ:AAPL) distance from 50-day simple moving average (SMA50) is -7.45%.
Apple Inc. (NASDAQ:AAPL) never fails to amaze its users. If your opinion differs from ours, this discreetly rolled out app by the company, dubbed” Indoor Survey”, will definitely change your mind. The app spotted first by a developer named,Steve Troughton-Smith, uses Radio frequency to map out an interior of a building.
On 02 November, Cintas Corporation (NASDAQ:CTAS) shares advanced 0.33% and was closed at $93.40. CTAS EPS growth in last 5 year was 19.50%. Cintas Corporation (NASDAQ:CTAS) year to date (YTD) performance is 19.07%.
Cintas Corporation (NASDAQ: CTAS) announced that its location in Baltimore, MD received Voluntary Protection Program (VPP) Star certification from the Maryland Occupational Safety and Health (MOSH). VPP Star is their highest recognition for the practice of and commitment to exemplary occupational safety and health. The VPP star recognition is achieved only when a business meets very detailed and comprehensive safety requirements,” stated Rick Gerlach, Sr. Director of Safety and Health. “We are proud of the local management team and front-line partners working together toward the common goal of eliminating workplace injuries
Cellectis S.A. (NASDAQ:CLLS) shares advanced 18.49% in last trading session and ended the day at $31.34. CLLS Gross Margin is 48.60% and its has a return on assets of -4.80%. Cellectis S.A. (NASDAQ:CLLS) quarterly performance is -9.89%.
Cellectis S.A. (NASDAQ:CLLS) has completed three production runs of its off-the-shelf CAR-T therapy under GMP conditions. The news sent shares in Cellectis up by 20% in early trading in Paris, emphasizing the key role manufacturing know-how is seen as playing in the upcoming immuno-oncology scrap. Paris, France-based Cellectis has stepped up the development of its manufacturing plans this year, bringing Arjan Roozen on board to oversee the operation in March and presenting a poster at ASCO several months later. The drive has brought the gene-editing specialist to the point at which it can produce its Servier-partnered lead candidate UCART19 under regulatory-grade conditions. While the big questions about the safety and efficacy of the drug are yet to be answered, the production runs cut the risk of Cellectis’ allogeneic CAR-T therapies being impeded by manufacturing issues.
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) caters to the Healthcare space. Its weekly performance is 32.73%. On the last day of trading company shares ended up at $4.38.
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), provided a business update and reported financial results for the three and nine months ended September 30, 2015. On September 9, 2015, AcelRx announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) in patients with moderate-to-severe acute pain following ambulatory abdominal surgery. On September 22, 2015, AcelRx announced that the European Commission (EC) approved Zalviso™ (sufentanil sublingual tablet system) for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting. The marketing authorization is granted for the 28 EU member states as well as for the European Economic Area (EEA) countries,Norway, Iceland and Liechtenstein. Net income for the third quarter of 2015 was $5.1 million, or $0.11 basic and diluted net income per share, compared to net income of$0.7 million, or $0.02 basic net income per share, and $0.13 diluted net loss per share for the third quarter of 2014. The increase in net income and net income per share was primarily due to revenue recognized under AcelRx’s CLA with Grunenthal for Zalviso, and AcelRx’s contract with the Department of Defense (DoD) for ARX-04 development.
Leave a Reply